GlassScriptPhysician profile
Alicia Turner
NPI 1861866717
$17,879.32
in general payments reported to CMS, 2019-2025
9 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,655 · 2023: $11K · 2024: $490 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,564 · Food and Beverage: $2,171 · Travel and Lodging: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,564.00 |
| Food and Beverage | $2,170.56 |
| Travel and Lodging | $1,490.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $14,595.99 | 2022-2025 | |
| Chiesi USA, INC. | $1,158.26 | 2022-2024 | Elfabrio |
| Takeda Pharmaceuticals U.S.A., INC. | $1,085.00 | 2023 | |
| Biomarin Pharmaceutical INC. | $417.25 | 2022-2025 | Voxzogo 1.2mg |
| Horizon Therapeutics Plc | $232.68 | 2022-2023 | Ravicti |
| Ptc Therapeutics, INC. | $195.67 | 2025 | Sephience |
| Alexion Pharmaceuticals, INC. | $108.38 | 2023 | Koselugo |
| Zevra Therapeutics INC | $43.05 | 2025 | Olpruva |
| Ultragenyx Pharmaceutical INC. | $43.04 | 2023 | Dojolvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.